Cargando…

Initial clinical applications treating pediatric and adolescent patients using MR-guided radiotherapy

PURPOSE: To demonstrate the clinical applications and feasibility of online adaptive magnetic resonance image guided radiotherapy (MRgRT) in the pediatric, adolescent and young adult (AYA) population. METHODS: This is a retrospective case series of patients enrolled onto a prospective study. All ped...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozak, Margaret M., Crompton, David, Gross, Brandie A., Harshman, Lyndsay, Dickens, David, Snyder, Jeffrey, Shepard, Andrew, St-Aubin, Joël, Dunkerley, David, Hyer, Daniel, Buatti, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676495/
https://www.ncbi.nlm.nih.gov/pubmed/36419881
http://dx.doi.org/10.3389/fonc.2022.962926
_version_ 1784833609522216960
author Kozak, Margaret M.
Crompton, David
Gross, Brandie A.
Harshman, Lyndsay
Dickens, David
Snyder, Jeffrey
Shepard, Andrew
St-Aubin, Joël
Dunkerley, David
Hyer, Daniel
Buatti, John M.
author_facet Kozak, Margaret M.
Crompton, David
Gross, Brandie A.
Harshman, Lyndsay
Dickens, David
Snyder, Jeffrey
Shepard, Andrew
St-Aubin, Joël
Dunkerley, David
Hyer, Daniel
Buatti, John M.
author_sort Kozak, Margaret M.
collection PubMed
description PURPOSE: To demonstrate the clinical applications and feasibility of online adaptive magnetic resonance image guided radiotherapy (MRgRT) in the pediatric, adolescent and young adult (AYA) population. METHODS: This is a retrospective case series of patients enrolled onto a prospective study. All pediatric (age < 18) and AYA patients (age< 30), treated on the Elekta Unity MR linear accelerator (MRL) from 2019 to 2021 were enrolled onto a prospective registry. Rationale for MRgRT included improved visualization of and alignment to the primary tumor, re-irradiation in a critical area, ability to use smaller margins, and need for daily adaptive replanning to minimize dose to adjacent critical structures. Step-and-shoot intensity-modulated radiation treatment (IMRT) plans were generated for all Unity patients with a dose grid of 3 mm and a statistical uncertainty of < 1% per plan. RESULTS: A total of 15 pediatric and AYA patients have been treated with median age of 13 years (range: 6 mos - 27 yrs). Seven patients were <10 yo. The clinical applications of MRgRT included Wilms tumor with unresectable IVC thrombus (n=1), Ewing sarcoma (primary and metastatic, n=3), recurrent diffuse intrinsic pontine glioma (DIPG, n=2), nasopharyngeal carcinoma (n=1), clival chordoma (n=1), primitive neuroectodermal tumor of the pancreas (n=1), recurrent gluteo-sacral germ cell tumor (n=1), C-spine ependymoma (n=1), and posterior fossa ependymoma (n=1). Two children required general anesthesia. One AYA patient could not complete the MRgRT course due to tumor-related pain exacerbated by longer treatment times. Two AYA patients experienced anxiety related to treatment on the MRL, one of which required daily Ativan. No patient experienced treatment interruptions or unexpected toxicity. CONCLUSION: MRgRT was well-tolerated by pediatric and AYA patients. There was no increased use of anesthesia outside of our usual practice. Dosimetric advantages were seen for patients with tumors in critical locations such as adjacent to or involving optic structures, stomach, kidney, bowel, and heart.
format Online
Article
Text
id pubmed-9676495
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96764952022-11-22 Initial clinical applications treating pediatric and adolescent patients using MR-guided radiotherapy Kozak, Margaret M. Crompton, David Gross, Brandie A. Harshman, Lyndsay Dickens, David Snyder, Jeffrey Shepard, Andrew St-Aubin, Joël Dunkerley, David Hyer, Daniel Buatti, John M. Front Oncol Oncology PURPOSE: To demonstrate the clinical applications and feasibility of online adaptive magnetic resonance image guided radiotherapy (MRgRT) in the pediatric, adolescent and young adult (AYA) population. METHODS: This is a retrospective case series of patients enrolled onto a prospective study. All pediatric (age < 18) and AYA patients (age< 30), treated on the Elekta Unity MR linear accelerator (MRL) from 2019 to 2021 were enrolled onto a prospective registry. Rationale for MRgRT included improved visualization of and alignment to the primary tumor, re-irradiation in a critical area, ability to use smaller margins, and need for daily adaptive replanning to minimize dose to adjacent critical structures. Step-and-shoot intensity-modulated radiation treatment (IMRT) plans were generated for all Unity patients with a dose grid of 3 mm and a statistical uncertainty of < 1% per plan. RESULTS: A total of 15 pediatric and AYA patients have been treated with median age of 13 years (range: 6 mos - 27 yrs). Seven patients were <10 yo. The clinical applications of MRgRT included Wilms tumor with unresectable IVC thrombus (n=1), Ewing sarcoma (primary and metastatic, n=3), recurrent diffuse intrinsic pontine glioma (DIPG, n=2), nasopharyngeal carcinoma (n=1), clival chordoma (n=1), primitive neuroectodermal tumor of the pancreas (n=1), recurrent gluteo-sacral germ cell tumor (n=1), C-spine ependymoma (n=1), and posterior fossa ependymoma (n=1). Two children required general anesthesia. One AYA patient could not complete the MRgRT course due to tumor-related pain exacerbated by longer treatment times. Two AYA patients experienced anxiety related to treatment on the MRL, one of which required daily Ativan. No patient experienced treatment interruptions or unexpected toxicity. CONCLUSION: MRgRT was well-tolerated by pediatric and AYA patients. There was no increased use of anesthesia outside of our usual practice. Dosimetric advantages were seen for patients with tumors in critical locations such as adjacent to or involving optic structures, stomach, kidney, bowel, and heart. Frontiers Media S.A. 2022-11-07 /pmc/articles/PMC9676495/ /pubmed/36419881 http://dx.doi.org/10.3389/fonc.2022.962926 Text en Copyright © 2022 Kozak, Crompton, Gross, Harshman, Dickens, Snyder, Shepard, St-Aubin, Dunkerley, Hyer and Buatti https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kozak, Margaret M.
Crompton, David
Gross, Brandie A.
Harshman, Lyndsay
Dickens, David
Snyder, Jeffrey
Shepard, Andrew
St-Aubin, Joël
Dunkerley, David
Hyer, Daniel
Buatti, John M.
Initial clinical applications treating pediatric and adolescent patients using MR-guided radiotherapy
title Initial clinical applications treating pediatric and adolescent patients using MR-guided radiotherapy
title_full Initial clinical applications treating pediatric and adolescent patients using MR-guided radiotherapy
title_fullStr Initial clinical applications treating pediatric and adolescent patients using MR-guided radiotherapy
title_full_unstemmed Initial clinical applications treating pediatric and adolescent patients using MR-guided radiotherapy
title_short Initial clinical applications treating pediatric and adolescent patients using MR-guided radiotherapy
title_sort initial clinical applications treating pediatric and adolescent patients using mr-guided radiotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676495/
https://www.ncbi.nlm.nih.gov/pubmed/36419881
http://dx.doi.org/10.3389/fonc.2022.962926
work_keys_str_mv AT kozakmargaretm initialclinicalapplicationstreatingpediatricandadolescentpatientsusingmrguidedradiotherapy
AT cromptondavid initialclinicalapplicationstreatingpediatricandadolescentpatientsusingmrguidedradiotherapy
AT grossbrandiea initialclinicalapplicationstreatingpediatricandadolescentpatientsusingmrguidedradiotherapy
AT harshmanlyndsay initialclinicalapplicationstreatingpediatricandadolescentpatientsusingmrguidedradiotherapy
AT dickensdavid initialclinicalapplicationstreatingpediatricandadolescentpatientsusingmrguidedradiotherapy
AT snyderjeffrey initialclinicalapplicationstreatingpediatricandadolescentpatientsusingmrguidedradiotherapy
AT shepardandrew initialclinicalapplicationstreatingpediatricandadolescentpatientsusingmrguidedradiotherapy
AT staubinjoel initialclinicalapplicationstreatingpediatricandadolescentpatientsusingmrguidedradiotherapy
AT dunkerleydavid initialclinicalapplicationstreatingpediatricandadolescentpatientsusingmrguidedradiotherapy
AT hyerdaniel initialclinicalapplicationstreatingpediatricandadolescentpatientsusingmrguidedradiotherapy
AT buattijohnm initialclinicalapplicationstreatingpediatricandadolescentpatientsusingmrguidedradiotherapy